September 28, 2016 Clinical Research/Diagn. Product Launch

Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases

Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics... Read more

September 19, 2016 Cell Analysis Tools Clinical Research/Diagn. Product Launch

CE marked MACS® IVD Antibodies by Miltenyi Biotec – Compliant with IVDD and produced according to ISO 13485

BERGISCH GLADBACH, 19. September 2016 – Miltenyi Biotec has expanded its assortment of antibodies with a series of CE marked in vitro-diagnostic medical devices – MACS® IVD Antibodies. They can be used in both clinical flow cytometry and in the quality control of cellular products for translational research. The renowned biotech company from Bergisch Gladbach... Read more

September 1, 2016 Cell Analysis Tools Clinical Research/Diagn.

Cellular Dynamics to Realign Business Units to Better Serve Therapeutic and Life Science Customers

MADISON, WIS, September 1, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced that effective September 1, 2016 the company operations will be divided into two equally important business units. Emile Nuwaysir, PhD, President and Chief Operating Officer of CDI, will lead the Therapeutics Business Unit. The Life Science business unit will be led by... Read more

August 31, 2016 Acad, Gov/Utilities Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

Johns Hopkins and Salk Co-lead $15 Million Initiative to Unravel Bipolar Disorder and Schizophrenia

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Neurons iCell Astrocytes iCell DopaNeurons iCell GlutaNeurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts iCell Endothelial Cells... Read more

August 27, 2016 Clinical Research/Diagn. Product Launch

Boosting Compact Ultrasound IQ: GE Healthcare’s New Vivid™ iq Combines Power and Portability

Rome – 27 August 2016 – In the lead up to the European Society of Cardiology Congress in Rome Italy, GE Healthcare today announced the global commercial launch[1] of its new generation of high-end portable compact cardiovascular ultrasound, the Vivid™ iq. A smaller sized compact weighing just 4.5 kg, the Vivid™ iq matches exceptional image... Read more

August 23, 2016 Clinical Research/Diagn. Industrial Licensing, IP, and Legal

GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents

Chalfont St Giles, UK – 23 August 2016 – In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of... Read more

July 21, 2016 Cell Analysis Tools Clinical Research/Diagn.

MACSxpress Treg Isolation Kit, human: Quick and efficient isolation of regulatory T cells

BERGISCH GLADBACH, July 21, 2016 – The new MACSxpress® Treg Isolation Kit, human from Miltenyi Biotec facilitates both the fast and efficient isolation of regulatory T (Treg) cells from a maximum of 30 ml of fresh, anticoagulated whole blood. The MACSxpress Technique makes it possible to isolate Treg cell populations without using density gradient centrifugation and... Read more

July 13, 2016 Clinical Research/Diagn. M&A, Partnerships

Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA

Chalfont St Giles, UK – 13 July 2016 – GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions and services for our cell therapy... Read more

June 21, 2016 Cell Analysis Tools Clinical Research/Diagn. Product Launch

New: The MACSPlex Exosome Kit, human from Miltenyi Biotec

AUTOMATED CHARACTERIZATION OF TINY VESICLES BERGISCH GLADBACH, June 21, 2016 – Miltenyi Biotec has extended its portfolio with the MACSPlex Exosome Kit, human. The fast and efficient process enables the characterization of 37 exosome surface markers in a single experiment. Studies indicate that the physiological significance of exosomes is not to be ignored. The molecular... Read more